12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Company News  |  Deals

Biogen Idec, Stromedix deal

Biogen Idec will acquire Stromedix for $75 million up front, and up to $487.5 million in milestones. Stromedix is developing STX-100, a humanized mAb against ...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >